STCUBE
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
052020 | KO
Overview
Corporate Details
- ISIN(s):
- KR7052020005
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강남구 영동대로 511 2201(삼성동, 무역센터 트레이드타워), 강남구
- Website:
- https://www.stcube.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
STCube is a clinical-stage biopharmaceutical company specializing in the development of first-in-class, precision-driven immunotherapies for cancer. The company's core focus is on its lead drug candidate, Nelmastobart, the world's first immune checkpoint inhibitor targeting the novel BTN1A1 protein. This target is highly expressed in chemo-refractory and resistant cancer cells, often in a mutually exclusive manner with PD-L1, offering a new therapeutic avenue for patients with unmet medical needs. Having successfully completed Phase 1 clinical trials confirming its safety and efficacy, Nelmastobart represents a potential treatment for various treatment-resistant cancers. STCube advances its pipeline through research, development, and biomarker-driven clinical trials, collaborating with leading global institutions and forming strategic partnerships with multinational pharmaceutical companies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-18 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.2 KB | ||
| 2025-08-25 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (면역항암제 hSTC810 의 미국 식품의약국(FDA) 제1b/2상 임상…
|
Korean | 14.5 KB | ||
| 2025-08-25 00:00 |
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (Nelmastobart(hSTC810)의 진행성/전이성 비소세포폐암 제2…
|
Korean | 9.1 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-06-30 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.3 MB | ||
| 2025-03-20 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획승인신청등결정) (면역항암제 Nelmastobart(hSTC810)의 전이성/재발성 …
|
Korean | 13.1 KB | ||
| 2025-03-19 00:00 |
Post-Annual General Meeting Information
정기주주총회결과
|
Korean | 29.9 KB | ||
| 2025-03-19 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 10.7 KB | ||
| 2025-03-11 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 25.6 KB | ||
| 2025-03-11 00:00 |
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
|
Korean | 504.8 KB | ||
| 2025-03-04 00:00 |
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
|
Korean | 190.4 KB | ||
| 2025-02-28 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 202.3 KB | ||
| 2025-02-28 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 186.5 KB |
Automate Your Workflow. Get a real-time feed of all STCUBE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for STCUBE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for STCUBE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
